Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations
Show Less
1
Department of Obstetrics and Gynecology, Cine State Hospital, Aydin
2
Department of Obstetrics and Gynecology, Adnan Menderes University, Aydin
3
Department of Biochemistry, Adnan Menderes University, Aydin (Turkey)
Clin. Exp. Obstet. Gynecol. 2011, 38(1), 54–56;
Published: 10 March 2011
Abstract
Objective: The objective of the current study was to investigate the effect of a combined oral contraceptive (COC) containing 20 ug ethinyl estradiol (EE) and 100 ug levonorgestrel (LNG) which is currently used on plasma plasminogen activator inhibitor-1 (PAI-1) concentrations. Material and Methods: Twenty-five women who had not used any COC for at least three months before the initiation of the study were enrolled in the control group. Twenty women who had been using COC containing 20 ug EE and 100 ug levonorgestrel LNG for at least three months prior to the study were enrolled in the LNG/EE group. Serum samples for PAI-1 and other biochemical parameters were obtained at the early follicular phase (cycle day 2-5). Results: No significant difference was observed in PAI-1 concentrations between the LNG/EE and control group (group LNG/EE: 62.4 ± 30.2 ng/ml; control group: 58.7 ± 26.0 ng/ml). Conclusion: Although we observed similar PAI-1 concentrations in both groups, there is need for further interventions to evaluate the clinical relevance of our findings.;">
Keywords
PAI-1
Low-dose oral contraceptives
Levonorgestrel